A Phase 2, Randomized, Double-Blind, Placebo Controlled Study Evaluating the Safety, Tolerability, and Efficacy of GS-9674 in Subjects With Primary Sclerosing Cholangitis Without Cirrhosis

Trial Profile

A Phase 2, Randomized, Double-Blind, Placebo Controlled Study Evaluating the Safety, Tolerability, and Efficacy of GS-9674 in Subjects With Primary Sclerosing Cholangitis Without Cirrhosis

Recruiting
Phase of Trial: Phase II

Latest Information Update: 27 Jul 2017

At a glance

  • Drugs GS 9674 (Primary)
  • Indications Primary sclerosing cholangitis
  • Focus Adverse reactions
  • Sponsors Gilead Sciences
  • Most Recent Events

    • 19 May 2017 Planned End Date changed from 1 Jan 2020 to 1 Feb 2020.
    • 11 Apr 2017 Planned End Date changed from 1 Aug 2019 to 1 Jan 2020.
    • 11 Apr 2017 Planned primary completion date changed from 1 Sep 2017 to 1 Oct 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top